Unique, practical knowledge for nurses responsible for daily management of patients with cardiovascular disease, diabetes and related conditions.

Wednesday, 04 January 2017

A new study suggests that a ‘Sit Less’ intervention ‒ breaking sitting with standing and light-intensity walking ‒ may be an alternative to structured exercise to promote blood sugar control in patients with type 2 diabetes, giving improved 24-hour glucose levels and improved insulin sensitivity.

Topics covered:
Wednesday, 04 January 2017

Adding evolocumab to optimised statin therapy results in statistically significant regression of atherosclerosis in patients with coronary artery disease, according to results from the GLAGOV phase 3 trial.

Topics covered:
Wednesday, 04 January 2017

Tackling obesity by offering the opportunity to attend a weight loss programme during a routine consultation is effective, welcomed by patients and takes only 30 seconds, according to a new randomised trial of over 1800 people in the UK.

Topics covered:
Monday, 19 December 2016

The UK charity Heart Valve Voice has developed the first practical guidance in heart valve disease for primary care. The disease is under-diagnosed and yet is increasing in prevalence as the population ages, so there is a need for primary care to plan an appropriate response.

Category: Editorial
Thursday, 27 October 2016
Targeting cardiovascular disease risk factors may be important across a person’s lifetime, as a new study from the US National Institutes of Health shows that efforts to prevent risk factors should extend to those over 65 years of age.
Topics covered:
Thursday, 27 October 2016
Semaglutide, an investigational human glucagon-like peptide-1 (GLP-1) analogue, significantly reduced the risk of the primary composite endpoint of time to first occurrence of cardiovascular (CV) death, non-fatal myocardial infarction or non-fatal stroke by 26% vs placebo, when added to standard of care in adults with type 2 diabetes at high CV risk.
Topics covered:
Thursday, 27 October 2016
Our regular Evidence in Practice feature summarizes recent scientific papers focusing on different aspects of cardiovascular medicine. This month, we feature a major review published recently in The Lancet suggesting that the benefits of statin therapy have been repeatedly underestimated, and the harms exaggerated, due to misinterpretation of the evidence.
Friday, 21 October 2016

Sacubitril/valsartan (Entresto), the first angiotensin receptor-neprilysin inhibitor (ARNI), is a recently licensed medication that has been shown to improve outcomes for patients with symptomatic chronic HF with reduced ejection fraction (HF-REF) compared with current gold-standard treatment with an ACE inhibitor. This article describes the pharmacist’s role in supporting patients receiving sacubitril/valsartan.

Category: Editorial
Topics covered:
Friday, 21 October 2016

Commissioning is not so different from seeing patients. As a GP you listen, examine, draw up a diagnosis and plan treatment. In commissioning, the community served by the clinical commissioning group (CCG) is the ‘patient’. When considering the introduction of a new treatment for heart failure (HF) such as sacubitril/valsartan (Entresto), we must consider not only its acquisition costs but also its potential benefits in improving patients' symptoms and reducing expensive hospital admissions.

Category: Editorial
Topics covered:
Friday, 21 October 2016

Many patients with heart failure rely on practice nurses to monitor their care. A multidisciplinary team (MDT) integrated community approach has been endorsed by NICE guidelines when delivering HF care. This article provides practice nurses with the information they need to understand the condition, current treatment guidelines, and the new treatment – sacubitril/valsartan, the first-in-class angiotensin receptor-neprilysin inhibitor.

Category: Editorial
Topics covered:

Article search and filter